SLC35A2基因突变致先天性糖基化障碍1例

doi:10.6040/j.issn.1671-7554.0.2020.1529

摘要/Abstract

摘要： 目的对1例反复抽搐伴发育落后患儿的临床特点及致病基因进行分析。方法回顾性分析患儿的临床资料及基因检测结果,并复习相关文献。结果患儿,男,生后1个月左右出现反复抽搐,伴发育落后等症状;体格检查下腹部、右腿部及背部可见色素脱失斑;视频脑电图提示周期性爆发抑制伴高度失律背景;颅脑磁共振提示双侧侧脑室旁脑白质异常信号。采用高通量测序法,发现患儿SLC35A2基因(NM_001042498)第2号外显子存在1个杂合错义突变c.262G>C(P.A88P);家系分析显示父母亲该位点无变异,为自发突变,诊断为SLC35A2-CDG。给予托吡酯、氯硝西泮、左乙拉西坦、拉莫三嗪等抗癫痫药及促肾上腺皮质激素治疗,抽搐发作较前减少。结论 SLC35A2-CDG是一种由X连锁显性遗传引起的糖蛋白合成障碍的罕见的遗传代谢病,目前尚无有效治疗方法,基因检测有助于明确诊断。

关键词: 先天性糖基化障碍, SLC35A2基因, 基因突变, 癫痫, 发育迟缓

Abstract: Objective To explore the clinical manifestations and genetic basis of a patient with recurrent epileptic seizures and global developmental delay. Methods The clinical data and genetic test results of the patient were analyzed retrospectively and related literature was reviewed. Results The patient, a boy, whose main clinical features were recurrent epileptic seizures and developmental delay that started from about 1 month after birth. Physical examination showed hypopigmentation on the lower abdomen, right leg and back. Video electroencephalogram(EEG)suggested abnormal infant electroencephalogram, periodic burst inhibition with hypsarrhythmia; cerebral magnetic resonance imaging(MRI)indicated abnormal signal in the bilateral periventricular white matter. Next generation sequencing detected that the patient carried a heterozygous de novo mutation of c.262G>C(P.A88P)in SLC35A2 gene(NM_001042498), which was a spontaneous mutation. After use of antiepileptic drugs such as topiramate, clonazepam, levetiracetam and lamotrigine and treatment with adrenocorticotropic hormone(ACTH)in combination, the seizure frequency was decreased. Conclusion SLC35A2-CDG is a metabolic disease caused by X-linked dominant inheritance of glycoprotein synthesis defects. Currently there is no effective treatment and the suspected cases can get a definite diagnosis by gene detection.

Key words: Congenital disorder of glycosylation, SLC35A2 gene, Gene mutation, Epilepsy, Developmental delay

中图分类号:

R729

孙宇,陈娜,马爱华. SLC35A2基因突变致先天性糖基化障碍1例[J]. 山东大学学报 (医学版), 2021, 59(4): 113-116.

SUN Yu, CHEN Na, MA Aihua. A case of congenital disorder of glycosylation caused by SLC35A2 gene mutation[J]. Journal of Shandong University (Health Sciences), 2021, 59(4): 113-116.

参考文献

[1] Jaeken J, Vanderschueren-lodeweyckx M, Casaer P, et al. Familial psychomotor retardation with markedly fluctuating serum prolactin, FSH and GH levels, partial TBG-deficiency, increased serum arylsulphatase A and increased CSF protein: a new syndrome? [J]. Pediatr Res, 1980, 14(2): 179-179.
[2] Kodera H, Nakamura K, Osaka H, et al. De novo mutations in SLC35A2 encoding a UDP-galactose transporter cause early-onset epileptic encephalopathy [J]. Hum Mutat, 2013, 34(12): 1708-1714.
[3] Witters P, Shawn T, Barone R, et al. Clinical and biochemical improvement with galactose supplementation in SLC35A2-CDG[J]. Genet Med, 2020, 22(6): 1102-1107.
[4] Vals M, Angel A, Pilvi I, et al. Clinical, neuroradiological, and biochemical features of SLC35A2-CDG patients [J]. J Inherit Metab Dis, 2019, 42(3): 553-564.
[5] Miyamoto S, Mitsuko N, Ohashi T, et al. A case of de novo splice site variant in SLC35A2 showing developmental delays, spastic paraplegia, and delayed myelination [J]. Mol Genet Genomic Med, 2019, 7(8): e814. doi: 10.1002/mgg3.814.
[6] Michelle D, Ilaria G, Deguzman C, et al. Diagnostic yield and treatment impact of targeted exome sequencing in early-onset epilepsy[J]. Front Neurol, 2019, 10: 434. doi: 10.3389/fneur.2019.00434.
[7] Ng BG, Paulina S, Satish A, et al. SLC35A2-CDG: Functional characterization, expanded molecular, clinical, and biochemical phenotypes of 30 unreported Individuals [J]. Hum Mutat, 2019, 40(7): 908-925.
[8] Yates TM, Suri M, Archana D, et al. SLC35A2-related congenital disorder of glycosylation: Defining the phenotype [J]. EEur J Paediatr Neurol, 2018, 22(6): 1095-1102.
[9] Andrew NH, Bevilacqua J, Shankar K, et al. Retrospective genotype-phenotype analysis in a 305 patient cohort referred for testing of a targeted epilepsy panel[J]. Epilepsy Res, 2018, 144(144): 53-61.
[10] Kristen W, Kyriakie S, Speltz LC, et al. Mosaicism of the UDP-Galactose transporter SLC35A2 in a female causing a congenital disorder of glycosylation: a case report [J]. BMC Med Genet, 2018, 19(1): 100.
[11] Kimizu T, Takahashi Y, Taikan O, et al. A case of early onset epileptic encephalopathy with de novo mutation in SLC35A2: Clinical features and treatment for epilepsy [J]. Brain Dev, 2017, 39(3): 256-260.
[12] Fátima L, Barbosa M, Ameur A, et al. Identification of novel genetic causes of Rett syndrome-like phenotypes [J]. J Med Genet, 2016, 53(3): 190-199.
[13] Doerre K, Olczak M, Wada Y, et al. A new case of UDP-galactose transporter deficiency(SLC35A2-CDG): molecular basis, clinical phenotype, and therapeutic approach [J]. J Inherit Metab Dis, 2015, 38(5): 931-940.
[14] Hino-fukuyo N, Atsuo K, Arai-ichinoi N, et al. Genomic analysis identifies candidate pathogenic variants in 9 of 18 patients with unexplained West syndrome [J]. Hum Genet, 2015, 134(6): 649-658.
[15] Daniëlle GM Bosch, F Nienke Boonstra, Nicole de Leeuw, et al. Novel genetic causes for cerebral visual impairment [J]. Eur J Hum Genet, 2016, 24(5): 660-665.
[16] 郎长会, 杨莹, 牛雪阳, 等. SLC35A2基因变异相关的先天性糖基化障碍Ⅱ型临床表型特点[J]. 中华儿科杂志, 2020, 58(7): 586-590. LANG Changhui, YANG Ying, NIU Xueyang, et al. Clinical characteristics of SLC35A2 gene variants related congenital disorders of glycosylation type Ⅱ [J]. Zhonghua Er Ke Za Zhi, 2020, 58(7): 586-590.
[17] 田杨,侯池,王秀英,等. SLC35A2基因突变致马凡综合征家系中West综合征患儿1例报告并文献复习[J]. 临床儿科杂志, 2020, 38(4): 302-305. TIAN Yang, HOU Chi, WANG Xiuying, et al. Clinical characteristics analysis of a child with West syndrome caused by SLC35A2 gene mutation in a Marfan syndrome family and literature review[J]. Journal of Clinical Pediatrics, 2020, 38(4): 302-305.
[18] Sim NS, Seo Y, Lim JS, et al. Brain somatic mutations in SLC35A2 cause intractable epilepsy with aberrant N-glycosylation[J]. Neurol Genet, 2018, 4(6): e294. doi: 10.1212/NXG.0000000000000294.
[19] Hudson HF, Eklund E A, Bobby GN, et al. Neurology of inherited glycosylation disorders [J]. Lancet Neurol, 2012, 11(5): 453-466.

相关文章 15

[1]	葛丽娟金瑞峰王纪文许新升李癊. 多药耐药基因1 C1236T多态性与癫痫患者对药物反应性的相关性[J]. 山东大学学报(医学版), 2209, 47(6): 99-102.
[2]	郑苏,陈述花,李华,邓劼,陈春红,王晓慧,冯卫星,韩萧迪,张雨佳,李娜,李莫,方方. 脑电变化和BASED评分与54例婴儿痉挛症促肾上腺皮质激素疗效的相关性[J]. 山东大学学报 (医学版), 2022, 60(9): 91-96.
[3]	李军,李保敏,杨璐. UBA5 基因突变致早发性癫痫性脑病临床特征与遗传学分析[J]. 山东大学学报 (医学版), 2022, 60(8): 58-62.
[4]	田敏,曹丽丽,宋承远. 神经纤维瘤病Ⅰ型:新发突变1例并文献复习[J]. 山东大学学报 (医学版), 2022, 60(4): 128-132.
[5]	宋洛卿,周国钰,叶翔,卢梅,赵新静. 脑淀粉样血管病相关炎症长期误诊1例报道并文献复习[J]. 山东大学学报 (医学版), 2022, 60(4): 119-122.
[6]	薛美娟,石艳,邵琳琳,王琳,张昀,张阿敏. 遗传性血栓性血小板减少性紫癜1例并文献复习[J]. 山东大学学报 (医学版), 2022, 60(3): 121-124.
[7]	亓梦雨,周敏然,孙洺山,李世洁,陈春燕. T大颗粒淋巴细胞白血病合并原发性骨髓纤维化1例[J]. 山东大学学报 (医学版), 2022, 60(2): 118-120.
[8]	潘鹏飞,徐立升,纪坤乾,王得翔,李玉. 以呼吸衰竭起病的线粒体肌病1例及文献回顾[J]. 山东大学学报 (医学版), 2022, 60(2): 54-59.
[9]	史本康,陈守臻,曲思凤,王勇,刘磊. 临床常见快速进展前列腺癌临床特点及研究进展[J]. 山东大学学报 (医学版), 2021, 59(9): 110-116.
[10]	卢游,且迪,伍晋辉,杨凡. 干预Sonic Hedgehog信号通路对宫内发育迟缓新生大鼠学习记忆能力的影响[J]. 山东大学学报 (医学版), 2021, 59(5): 82-89.
[11]	黄秀丽,刘丙菊,孙立锋. PIK3CD基因突变致PI3Kδ过度活化综合征1例并文献复习[J]. 山东大学学报 (医学版), 2021, 59(3): 107-112.
[12]	郭玲玲,车超,陈坤平,柴润玉,杨秉上,曹爱华. 316例语言发育落后儿童的“五不”行为观察[J]. 山东大学学报 (医学版), 2021, 59(2): 95-101.
[13]	王正阳,夏艳,师凯旋,陶琨,王小杰. 曲美替尼在卵巢癌中对PAX8的表达作用[J]. 山东大学学报 (医学版), 2021, 59(10): 23-29.
[14]	贾建华,陈思,吴倩倩,徐硕,李超,程莲,徐淑军. 立体定向脑电图引导下射频热凝毁损术治疗药物难治性癫痫的有效性分析[J]. 山东大学学报 (医学版), 2021, 59(10): 80-86.
[15]	刘娜,刘奇迹,牟凯,程翠云. EBF3基因杂合突变导致1例神经发育障碍综合征[J]. 山东大学学报 (医学版), 2020, 58(4): 105-109.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed